Detalles de la búsqueda
1.
Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy.
Eur J Med Chem
; 245(Pt 1): 114899, 2023 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36410169
2.
Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.
J Med Chem
; 66(18): 12950-12965, 2023 09 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676745
3.
Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, biological evaluation and preliminary SAR studies.
Eur J Med Chem
; 228: 114022, 2022 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34871843
4.
Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
J Med Chem
; 65(8): 6325-6337, 2022 04 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35426680
5.
Deep learning-driven scaffold hopping in the discovery of Akt kinase inhibitors.
Chem Commun (Camb)
; 57(81): 10588-10591, 2021 Oct 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34560776
Resultados
1 -
5
de 5
1
Próxima >
>>